衞士通(002268.SZ):股東中電科投資減持比例達1%
格隆匯8月23日丨衞士通(002268.SZ)公佈,公司於2021年8月23日收到公司股東中電科投資控股有限公司(“中電科投資”)《關於減持情況的吿知函》。中電科投資與公司控股股東中國電子科技網絡信息安全有限公司均為中國電子科技集團有限公司的全資子公司,為一致行動人。中電科投資於2021年8月12日至8月23日通過大宗交易的方式減持公司股份859.77萬股,持有的公司股份變動比例達到1%。
此次變動前,中電科投資持有16,298,813股公司股份,佔總股本的1.93%;此次變動後,中電科投資持有7,701,113股衞士通股份,佔總股本的0.91%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.